title: Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder.
abstract: OBJECTIVE
  Increased urinary bladder detrusor smooth muscle phasic contractility has been suggested to be associated with idiopathic bladder overactivity (OAB). We examined the role of voltage-dependent L-type calcium channels, adenosine triphosphate-sensitive potassium (K(ATP)) channels, and calcium-activated potassium (BK(Ca) and SK(Ca)) channels in the regulation of human detrusor phasic contractile activity.
  
  
  METHODS
  Isolated human bladder strip phasic contractions were measured and quantified as the mean area under the force-time curve, amplitude, and frequency of phasic contractions in 22 bladder samples.
  
  
  RESULTS
  Human detrusor strips displayed myogenic phasic contractions in the presence of atropine (10(-6) M), phentolamine (10(-6) M), propranolol (10(-6) M), suramin (10(-5) M), and tetrodotoxin (10(-6) M). The L-type calcium channel inhibitor nifedipine (300 nM) abolished the contractile activity. Blockade of K(ATP) channels by glibenclamide (1 and 10 microM) did not alter myogenic contractions. In contrast, the K(ATP) channel opener pinacidil (10 microM) markedly inhibited phasic contractility. Iberiotoxin (100 nM) and apamin (100 nM), potent and selective inhibitors of BK(Ca) and SK(Ca) channels, respectively, significantly increased the area under the force-time curve and the amplitude of contractions.
  
  
  CONCLUSIONS
  Phasic contractions of human detrusor are dependent on calcium entry through L-type calcium channels. BK(Ca) and SK(Ca) channels play a key role in the modulation of human detrusor smooth muscle phasic contractility. Furthermore, these observations support the concept that increasing conductance through K(ATP), BK(Ca), and SK(Ca) channels may represent attractive pharmacologic targets for decreasing phasic contractions of detrusor smooth muscle in OAB.
authors.affiliation: Pelvipharm, Domaine CNRS, Gif-sur-Yvette, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Darblade
authors.forename: Delphine
authors.initials: D
authors.lastname: Behr-Roussel
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Oger
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Hieble
authors.forename: Thierry
authors.initials: T
authors.lastname: Lebret
authors.forename: Diane
authors.initials: D
authors.lastname: Gorny
authors.forename: Gérard
authors.initials: G
authors.lastname: Benoit
authors.forename: Laurent
authors.initials: L
authors.lastname: Alexandre
authors.forename: François
authors.initials: F
authors.lastname: Giuliano
mesh_terms: D020746:Calcium Channels, L-Type / Q000187:drug effects / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects*; D015221:Potassium Channels / Q000187:drug effects* / Q000502:physiology*; D001743:Urinary Bladder / Q000187:drug effects* / Q000502:physiology*; D014549:Urinary Incontinence / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D020746:Calcium Channels, L-Type; D015221:Potassium Channels